Dr. Goldberg currently is a board certified ophthalmologist in Torrance, California and a managing partner at Wolstan and Goldberg Eye Associates. He is well known as a leader in laser vision correction surgery, refractive cataract surgery, and new techniques in corneal surgery and micro-invasive glaucoma surgery.
For patient convenience, Dr. Goldberg maintains surgical credentials at Torrance Memorial, Little Company of Mary Hospital, UCLA, Torrance Surgery Center, Surgery Center of the South Bay, and NVISION. Dr. Goldberg also serves as the Chief of Department at Torrance Memorial, an Affiliate of Cedar Sinai Medical Center.
Dr. Goldberg has an extensive background in research and has been a principle investigator in over seventy FDA clinical trials for new medical devices and medications.
Dr. Goldberg currently sits on the American Society of Cataract and Refractive Surgery (ASCRS) FDA committee. He is among the first to implement these new eye care technologies in his practice and offer them to his patients. Dr. Goldberg is currently welcoming new patients at Wolstan and Goldberg Eye Associates.
Damien F Goldberg, MD
Wolstan & Goldberg Eye Associates
23600 Telo Ave., #100
Torrance, CA 90505
Chief of Ophthalmology Surgery, Torrance Memorial Medical Center
Little Company of Mary Hospital, Torrance
Torrance Surgery Center
Chief of Ophthalmology Surgery
South Bay Surgery Center
NVISION Laser Center of Torrance
Clinical Instructor, Jules Stein Eye Institute, UCLA
Physicians And Surgeons License
National Board of Medical Examiners
Recent Certificates And Awards
2019 AAO Achievement Award
2018 ASCRS FDA Committee
2017 AECOS American Membership Committee
2017 Castle Connolly Top Doctors Award
2016 OSN Premier Surgeon 300 Innovators in Refractive Cataract Surgery Award
2015 Editorial Board of Cataract & Refractive Surgery Today
2015 Editorial Board of Ocular Surgery News
2013 Co-Editor of Millennial Eye Electronic Periodical
American Academy of Ophthalmology
American Society of Cataract and Refractive Surgeons
American Society of Research in Vision and Ophthalmology
Sjogren’s Syndrome Foundation
American Medical Association
2004-2005 Cornea, External Disease and Refractive Surgery Fellow,
Department of Ophthalmology
University of Texas Southwestern Medical Center
Department of Ophthalmology
Georgetown University / Washington National Eye Center
Department of Internal Medicine
Georgetown University Hospital
1995 – 2000 MD and MBA
Georgetown University, School of Medicine and
The Robert Emmett McDonough
School of Business
1991-1995 Bachelor of Science with High Honors, Biology, Anthropology and Human Biology
Honors: Magna Cum Laude
Lambda Alpha, Anthropology Honor Society
Dean’s List, 1992-1995
Dr. Goldberg, his wife and their three boys enjoy the active lifestyle that Southern California provides. Their main interests are local sports, like surfing, soccer, golf, traveling, reading and spending time with the family.
Corneal, External Disease and Refractive Surgery Specialty
English and Spanish
Telo Medical Building
23600 Telo. Ave Suite 100
Torrance, Ca 90505
1. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease. Yeu E, Goldberg DF, Mah FS, Beckman KA, Luchs JI, Solomon JD, White DE, Gupta PK.
Clin Ophthalmol. 2019 May 27;13:887-894.
2. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. Ophthalmology. 2019 Apr 6
3. Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2018 Oct 24
4. Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017 Aug 7;11:1423-1430.
5. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS, Buznego C, Gira JP, Goldberg DF, Goldman D, Goyal RK, Jackson MA, Katz J, Kim T, Majmudar PA, Malhotra RP, McDonald MB, Rajpal RK, Raviv T, Rowen S, Shamie N, Solomon JD, Stonecipher K, Tauber S, Trattler W, Walter KA, Waring GO 4th, Weinstock RJ, Wiley WF, Yeu E. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017 Jan;27 Suppl 1:3-47.
6. Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, Lee SS, Goodkin ML, Zhang J, Whitcup SM, Robinson MR; Bimatoprost SR Study Group (Goldberg DF) Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. Am J Ophthalmol. 2017 Mar; 175:137-147.
7. Goldstein MH, Martel JR, Sall K, Goldberg DF, Abrams M, Rubin J, Sheppard J, Tauber J, Korenfeld M, Agahigian J, Durham TA, Furfine E. Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2016 Jul 27.
8. Silverstein SM, Jackson MA, Goldberg DF, Muñoz M.The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery. Clin Ophthalmol. 2014 May 16;8:965-72.
9. Walters TR, Goldberg DF, Peace JH, Gow JA; Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014 Jan;121(1):25-33.
10. Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR Goldberg DF Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011 Sep;27(9):1693-703.
11. Goldberg DF. Preoperative evaluation of patients before cataract and refractive surgery. Int Ophthalmic Clin. 2011 spring; 51(2):97-107.
12. Wittpenn J, Silverstein S, Hunkler J, Schechter B, Price F, Chu R, Wallace B, Trattler W, Dougherty P, Goldberg D, Perry H, Solomon K, Donnfeld E, Kenyon K, Roberts C. A Masked Comparison of Acular LS® Plus Steriod versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients. Am J Ophthalmol. 2008 Oct;146(4):554-560. Epub 2008 Jul 2.
13. Petroll, WM, Goldberg DF, Lindsey SS, Kelley PS, MD, Cavanagh, DW, Bowman WR, Parmar DN, Verity SM, McCulley, JP. Confocal assessment of corneal response to intracorneal lens insertion and laser in situ keratomileusis with flap creation using IntraLase. Journal of Cataract & Refractive Surgery. 2006. Jul:32(7) 1119-28.
14. Goldberg DF. Implantation of the Phakic 6 H2 Intraocular Lens – A Heparin-Coated Phakic Intraocular Lens. Techniques in Ophthalmology. 4(1):7-11, March 2006.
15. Goldberg DF, Negvesky G, Butrus S, Goodlick T. Ulcerative Keratitis in Mycosis Fungoides. Eye and Contact Lens. 2005. Sept; 31(5) 219-20.
16. Goldberg D, Panigrahi D, Butrus S, Abelson M. Case of Rofecoxib Associated Steven Johnson Syndrome with Corneal and Conjunctival Changes. Cornea 2004 Oct 23(7):736-737.
17. Boxer Wachler B, Huynh VA, El-Shiaty A, Goldberg D, Evaluation of corneal functional optical zone after laser in situ keratomileusis. Journal of Cataract & Refractive Surgery 2002; 28:948–953.
18. Goldberg D, Hillyer C, Investigations in the Re-Synovialization of Cadaveric Patellar tendon Allografts p.1-32. Emory Biology Department 1995.